Holdaway I M, Frengley P A, Scott D J, Ibbertson H K
Clin Endocrinol (Oxf). 1978 Jan;8(1):45-54. doi: 10.1111/j.1365-2265.1978.tb01349.x.
Bromoergocryptine has been used to lower growth hormone concentrations in ten patients with acromegaly in whom previous attempts at pituitary ablation had failed to cure the disorder. Plasma immunoreactive and plasma receptor-reactive growth hormone concentrations together with plasma somatomedin concentrations and urinary excretion of immunoreactive growth hormone were used to assess the response to treatment. Casual immunoreactive hormone concentrations in plasma were lowered to less than 8 mu/l and to less than 5 mu/l during glucose infusion in seven patients, and urinary growth hormone excretion was also brought into the normal range (less than 40 micromicron/12 h) in this group. There was at least a 40% reduction in these measurements in the remaining three patients who had the highest basal hormone concentrations of the group. Plasma somatomedin fell with treatment in eight patients, and intravenous glucose tolerance improved in seven of eight patients tested. Used in modest dosage (up to 15 mg/day) bromoergocryptine can lower plasma and urinary growth hormone and plasma somatomedin concentrations in acromegalic patients in whom previous treatments had decreased but not cured hormone overproduction.
溴隐亭已被用于降低10例肢端肥大症患者的生长激素浓度，这些患者先前的垂体切除尝试未能治愈该疾病。血浆免疫反应性和血浆受体反应性生长激素浓度，以及血浆生长调节素浓度和免疫反应性生长激素的尿排泄量，被用于评估治疗反应。7例患者在葡萄糖输注期间，血浆中随意免疫反应性激素浓度降至低于8 μ g/l，在葡萄糖输注期间降至低于5 μ g/l，并且该组患者的尿生长激素排泄也进入正常范围（低于40 μ g/12小时）。在该组基础激素浓度最高的其余3例患者中，这些测量值至少降低了40%。8例患者的血浆生长调节素随治疗下降，在接受测试的8例患者中，7例患者的静脉葡萄糖耐量得到改善。以适度剂量（高达15 mg/天）使用时，溴隐亭可降低肢端肥大症患者的血浆和尿生长激素以及血浆生长调节素浓度，这些患者先前的治疗已降低但未治愈激素分泌过多。
